Mesynthes Ltd.
This article was originally published in Start Up
Executive Summary
Mesynthes Ltd.'s soft tissue regeneration and reconstruction platform, based on a proprietary extracellular matrix derived from the sheep forestomach, provides a biological template for tissue repair. Animal studies have demonstrated that the architecture of the matrix--including the vascular channels and the structural, fibrillar, and adhesive proteins, such as collagen and elastin--supports the ingress and growth of keratinocytes, fibroblasts, and mesenchymal and inflammatory cells. The extracellular matrix also releases important biological macromolecules that trigger tissue regeneration.
You may also be interested in...
Start-Up Previews (10/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.